Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

64.41USD
24 Apr 2015
Change (% chg)

$1.16 (+1.83%)
Prev Close
$63.25
Open
$63.15
Day's High
$64.52
Day's Low
$62.80
Volume
1,134,256
Avg. Vol
1,075,040
52-wk High
$68.74
52-wk Low
$47.37

TEVA.N

Chart for TEVA.N

About

Teva Pharmaceutical Industries Ltd (Teva) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva’s active pharmaceutical ingredient (API) business... (more)

Overall

Beta: 0.59
Market Cap(Mil.): $62,570.77
Shares Outstanding(Mil.): 959.35
Dividend: 0.35
Yield (%): 2.10

Financials

  TEVA.N Industry Sector
P/E (TTM): 18.06 41.06 41.71
EPS (TTM): 3.57 -- --
ROI: 8.76 16.86 16.20
ROE: 13.32 17.36 17.00
Search Stocks

Drug overlaps, shortages may complicate Teva bid for Mylan

NEW YORK - Teva Pharmaceutical Industries' bid for Mylan NV would create a company controlling nearly 25 percent of the U.S. generics market, including drugs in short supply, according to industry experts and a Reuters review of regulatory filings.

25 Apr 2015

DEALTALK-Drug overlaps, shortages may complicate Teva bid for Mylan

NEW YORK, April 24 - Teva Pharmaceutical Industries' bid for Mylan NV would create a company controlling nearly 25 percent of the U.S. generics market, including drugs in short supply, according to industry experts and a Reuters review of regulatory filings.

25 Apr 2015

Generic drugmaker Mylan goes hostile in bid for Perrigo

- Generic drugmaker Mylan NV said on Friday it would take its $31 billion offer for Perrigo Co Plc directly to shareholders, in what is set to be one of the most high-profile hostile takeover attempts of the year.

24 Apr 2015

Global healthcare M&A doubles versus 2014

LONDON, April 24 - Worldwide dealmaking in the healthcare sector has doubled this year compared with the same time in 2014, buoyed by Teva Pharmaceuticals Industries' unsolicited $40 billion bid for smaller rival Mylan this week, Thomson Reuters data shows.

24 Apr 2015

Deals of the day- Mergers and acquisitions

April 22 - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:

23 Apr 2015

Teva ready to divest operations to win regulatory nod for Mylan buy

- Generic drugmaker Teva Pharmaceutical Industries Ltd said it could "promptly" divest some operations to obtain regulatory clearance for its proposed $40 billion takeover of smaller rival Mylan NV .

22 Apr 2015

Teva's turnaround CEO sets sights on $40 billion mega-deal

TEL AVIV - Israeli turnaround specialist Erez Vigodman, the chief executive of Teva Pharmaceutical Industries , is looking to pull off the ultimate transformation with the biggest deal in Israel's corporate history.

22 Apr 2015

UPDATE 1-Teva ready to divest operations to win regulatory nod for Mylan buy

April 22 - Generic drugmaker Teva Pharmaceutical Industries Ltd said it could "promptly" divest some operations to obtain regulatory clearance for its proposed $40 billion takeover of smaller rival Mylan NV.

22 Apr 2015

UPDATE 1-Abbott says its payoff from Mylan deal surged

April 22 - Abbott Laboratories on Wednesday said its initial proceeds of $5.3 billion from the recent sale to Mylan of part of its generic drug business were now worth more than $7 billion because of appreciation of the stock it obtained in the deal.

22 Apr 2015

Teva ready to divest operations to win regulatory nod for Mylan buy

April 22 - Teva Pharmaceutical Industries Ltd said on Wednesday it could "promptly" divest some operations if necessary to obtain regulatory clearance for its proposed takeover of smaller rival Mylan NV.

22 Apr 2015

Competitors

  Price Chg
Novartis AG (NOVN.VX) CHF99.80 -0.80
Biogen Inc (BIIB.OQ) $401.71 -28.57

Earnings vs. Estimates

Search Stocks